Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
View Patent ↗This invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by the formula: wherein m is an integer of 1 to 3; n is an integer of 1 or 2; R 1 is a halogen atom or an optionally halogenated C 1-2 alkyl group; each of R 2 and R 3 is, same or different, a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R 4 is a group represented by the formula: wherein p is an integer of 2 to 5; R 5 is a C 1-4 alkyl group substituted by alkoxycarbonyl group, carbamoyl group, carbamoyloxy group, alkylsulfonyl group, alkylsulfinyl group, sulfamoyl group, carbamoylamino group, alkylsulfonylamino group, acylamino group, and the like; or a salt thereof and a pharmaceutical composition comprising thereof.
1. A compound represented by the formula:
wherein m is an integer of 1 to 3; n is an integer of 1 or 2; R 1 is a halogen atom or an optionally halogenated C 1-2 alkyl group; each of R 2 and R 3 is, same or different, a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R 4 is a group represented by the formula:
wherein p is an integer of 2 to 5; R 5 is a C 1-4 alkyl group substituted by optionally substituted alkoxycarbonyl group, optionally substituted carbamoyl group, optionally substituted cyclic aminocarbonyl group, optionally substituted carbamoyloxy group, optionally substituted cyclic aminocarbonyloxy group, optionally substituted alkylsulfonyl group, optionally substituted alkylsulfinyl group, optionally substituted sulfamoyl group, optionally substituted cyclic aminosulfonyl group, optionally substituted carbamoylamino group, optionally substituted cyclic aminocarbonylamino group, optionally substituted alkylsulfonylamino group or acylamino group; a prodrug thereof or a salt thereof.
2. The compound as defined in claim 1 , wherein R 1 is a halogen atom or trifluoromethyl group, or a salt thereof.
3. The compound as defined in claim 1 , wherein R 5 is methylsulfonylethyl group or methylsulfonylmethyl group, or a salt thereof.
4. The compound as defined in claim 1 , wherein both of R 2 and R 3 are hydrogen atoms, or a salt thereof.
5. The compound as defined in claim 1 , wherein one of R 2 and R 3 is a hydrogen atom, and the other is methyl group or methoxy group, or a sale thereof.
6. The compound as defined in claim 1 , wherein the compound is N,N-dimethyl-3-[1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-imidazol-2-yl]propanamide, N-methyl-3-[1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl)butyl)-1H-imidazol-2-yl]propanamide, 2-[(E)-2-(2,4-difluorophenyl)ethenyl]-4-{[4-(4-{2-[2-(methylsulfonyl)ethyl]-1H-imidazol-1-yl}butyl)phenoxy]methyl}-1,3-oxazole, 4-{[4-(4-}2-[(methylsulfonyl)methyl]-1H-imidazol-1-yl}butyl)phenoxy]methyl}-2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazole or 4-{[4-(4-{2-[2-(methylsulfonyl)ethyl]-1H-imidazol-1-yl}butyl)phenoxy]methyl}-2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazole, or a salt thereof.
7. A pharmaceutical composition, which comprises the compound as defined in claim 1 , or a salt thereof or a prodrug thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
8. The pharmaceutical composition as described in claim 7 , which is a HER2 tyrosine kinase inhibitor.
9. The pharmaceutical composition as described in claim 7 , which is for treating cancer selected from the group consisting of breast cancer, prostate cancer, lung cancer and pancreatic cancer.
10. A method for treating cancer selected from the group consisting of breast cancer, prostate cancer, lung cancer and pancreatic cancer, which comprises administering an effective amount of the compound as defined in claim 1 or a salt thereof or a pro-drug thereof to a mammal in need thereof.